New Generation Anti-Obesity Pharmacotherapy: Companion or Competitor to Metabolic bariatric Surgery?

•Bariatric surgery (BS) remains the most effective and durable treatment for severe obesity,•GLP-1 RAs have shown promise in patients with inadequate weight loss or recurrence after BS.•Despite robust weight reduction in clinical trials, GLP-RAs are unlikely to replace BS.•GLP-1 RAs may complement s...

Full description

Saved in:
Bibliographic Details
Published in:Drug discovery today 2024-08, Vol.29 (8), p.104072, Article 104072
Main Authors: Sahebkar, Amirhossein, Gadde, Kishore M., Kroh, Matthew, Eid, Ali H., Jamialahmadi, Tannaz
Format: Article
Language:English
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:•Bariatric surgery (BS) remains the most effective and durable treatment for severe obesity,•GLP-1 RAs have shown promise in patients with inadequate weight loss or recurrence after BS.•Despite robust weight reduction in clinical trials, GLP-RAs are unlikely to replace BS.•GLP-1 RAs may complement surgical procedures and improve weight loss.•Long-term safety and efficacy data of GLP-1 RAs in reducing cardiovascular outcomes are awaited.
ISSN:1359-6446
1878-5832
1878-5832
DOI:10.1016/j.drudis.2024.104072